Quantcast

Latest Ibritumomab tiuxetan Stories

2008-10-22 09:00:42

Tracon Pharmaceuticals, a biopharmaceutical company developing targeted therapies for cancer and eye diseases, has appointed Bryan Leigh its new chief medical officer. Dr Leigh has previously served as chief medical officer for Paramount Biosciences. Dr Leigh has also held positions at Genentech, Idec Pharmaceuticals, and Biogen Idec where he was responsible for global clinical oncology development, managing multiple clinical stage programs and marketed products including Rituxan and...

2008-10-21 09:00:53

SAN DIEGO, Oct. 21, 2008 (GLOBE NEWSWIRE) -- Tracon Pharmaceuticals, Inc., a biopharmaceutical company developing targeted therapies for cancer and eye diseases, today announced the appointment of Bryan Leigh, M.D. as Chief Medical Officer. Dr. Leigh previously served as Chief Medical Officer for Paramount Biosciences. He has also held positions at Genentech, IDEC Pharmaceuticals, and Biogen Idec where he was responsible for global clinical oncology development, managing multiple clinical...

2008-10-20 03:00:08

SEATTLE, Oct. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the results of an innovative study that investigated high (bone marrow ablative) dose Zevalin(R) ([90Y]-ibritumomab tiuxetan) followed by autologous stem cell infusions among 30 patients (median age 62 years) with relapsed/refractory or high risk aggressive non-Hodgkin's lymphoma (NHL) not eligible for a chemotherapy-based...

2008-10-16 03:00:08

SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the results of the First-line Indolent Trial (FIT) demonstrating that use of Zevalin(R)([90Y]-ibritumomab tiuxetan) in consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma provided important patient benefits including a significant improvement in progression free...

2008-10-07 09:00:55

Genentech and Biogen Idec have announced that a global Phase III study of Rituxan in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival, as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study. An independent review of the primary endpoint is being conducted for US...

2008-10-03 09:00:07

Cell Therapeutics, a biopharmaceutical company, has submitted a supplemental biologics license application to the FDA for use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. If approved, Zevalin would be the only radioimmunotherapy in the US with approval for use as first-line consolidation therapy. The company has requested priority review, which if granted, would result in a six month review period....

2008-10-02 03:00:18

SEATTLE, Oct. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. If approved, Zevalin would be the only radioimmunotherapy in the U.S. with approval for...

2008-09-24 03:00:09

By DeNardo, Gerald Advances in imaging technology have made it possible to view molecular pathways within living individuals as never before. However, molecular imaging and therapy have existed for more than a half-century and are based on long-established concepts and methods (see suggested references for support for statements made in this commentary). As molecular techniques come to the forefront in medicine, it has become clear that, just as a diversity of scientists is required to...

2008-09-22 12:00:38

Cell Therapeutics has announced that following a meeting with the FDA data from the first-line indolent trial would be sufficient to support a submission for a supplemental biologics license application. The supplemental biologics license application (sBLA) will propose a label expansion to include use of the Zevalin therapeutic regimen ((90Y)-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma...

2008-09-22 03:00:12

SEATTLE, Sept. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced today that following a meeting with the U.S. Food and Drug Administration (FDA) data from the First-line Indolent Trial (FIT) would be sufficient to support a submission for a supplemental Biologics License Application (sBLA). The sBLA will propose a label expansion to include use of the Zevalin(R) therapeutic regimen ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related